| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Rhodionin targets cytochrome P450 2D6 (CYP2D6), a key enzyme in drug metabolism. It is a specific, noncompetitive inhibitor with an IC50 of 0.761 µM and a Ki of 0.769 µM. It also targets acetylcholinesterase (AChE) and has antioxidant activity, as demonstrated by its DPPH free radical scavenging activity. It modulates signaling pathways such as NF-κB and MAPK and inhibits tumor cell proliferation and induces apoptosis.
|
|---|---|
| ln Vitro |
In vitro, Rhodionin is a specific, noncompetitive cytochrome P450 2D6 inhibitor with an IC50 of 0.761 μM and a Ki of 0.769 μM. It has potent DPPH free radical scavenging activity with an IC50 of 19.49 μM. It potently, concentration-dependently inhibits acetylcholinesterase (AChE) with an IC50 in the range of 57.50 to 2.43 μg/mL. It also inhibits tumor cell proliferation and induces apoptosis.
|
| ln Vivo |
In vivo, Rhodionin has an effect of nourishing and strengthening, clearing away heat and moistening the lungs. It is isolated from the roots of Rhodiola crenulata. Its ability to inhibit CYP2D6 suggests that it could have implications for interactions with co-administered drugs that are metabolized by this enzyme. Its antioxidant and anti-inflammatory activities suggest potential for in vivo protective effects.
|
| Enzyme Assay |
For cell-free assays, the CYP2D6 inhibitory activity of Rhodionin can be measured using a standard CYP450 activity assay. The compound is incubated with recombinant CYP2D6 enzyme, a specific substrate (e.g., dextromethorphan), and NADPH. The formation of the metabolite is measured by HPLC or LC-MS. The IC50 and Ki values are calculated from enzyme kinetics. Its antioxidant activity is measured using DPPH radical scavenging assays. Its AChE inhibitory activity is measured using Ellman's assay.
|
| Cell Assay |
For in vitro cellular assays, the effects of Rhodionin on CYP2D6 activity can be assessed in cells expressing the enzyme. Cells are treated with the compound, and the metabolism of a CYP2D6 probe substrate is measured. Its anticancer activity is assessed in cancer cell lines by measuring cell viability, apoptosis, and signaling pathway modulation (e.g., NF-κB, MAPK). Its antioxidant effects can be assessed by measuring ROS production in cells exposed to oxidative stress.
|
| Animal Protocol |
For in vivo studies, Rhodionin could be administered orally in animal models to study its effects on drug metabolism, specifically its potential to inhibit CYP2D6-mediated metabolism of co-administered drugs. Its antioxidant and anti-inflammatory effects could be studied in models of oxidative stress or inflammation. Its anticancer activity could be evaluated in xenograft models.
|
| ADME/Pharmacokinetics |
Rhodionin (CAS 85571-15-9) has a molecular formula of C21H20O11 and a molecular weight of 448.38 g/mol. Its chemical name is 7-[(6-deoxy-α-L-mannopyranosyl)oxy]-3,5,8-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one. Appearance: Yellow powder. Solubility: Soluble in methanol, ethanol, DMSO and other organic solvents. Storage: typical for flavonoids (desiccated, protected from light, -20°C). Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural flavonoid from Rhodiola crenulata, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. Its potent inhibition of CYP2D6 suggests a potential for drug-drug interactions, which would need to be carefully evaluated. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies.
|
| References |
|
| Additional Infomation |
Reports indicate that Rhodiola crenulata, Rhodiola sachalinensis, and Rhodiola rosea contain rhodioloside, and relevant data is available for reference.
Rhodionin is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying CYP2D6 inhibition, antioxidant activity, and anticancer mechanisms. Its mechanism of action involves noncompetitive inhibition of CYP2D6, scavenging of free radicals, and inhibition of AChE. It is a natural product from Rhodiola crenulata. No clinical trials have been reported. |
| Molecular Formula |
C21H20O11
|
|---|---|
| Molecular Weight |
448.3769
|
| Exact Mass |
448.1
|
| CAS # |
85571-15-9
|
| PubChem CID |
21626477
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
802.9±65.0 °C at 760 mmHg
|
| Flash Point |
284.4±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.755
|
| LogP |
0.44
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(C3=C(C(=C2)O)C(=O)C(=C(O3)C4=CC=C(C=C4)O)O)O)O)O)O
|
| InChi Key |
CIAXXTSXVCLEJK-JOEVVYSCSA-N
|
| InChi Code |
InChI=1S/C21H20O11/c1-7-13(24)16(27)18(29)21(30-7)31-11-6-10(23)12-15(26)17(28)19(32-20(12)14(11)25)8-2-4-9(22)5-3-8/h2-7,13,16,18,21-25,27-29H,1H3/t7-,13-,16+,18+,21-/m0/s1
|
| Chemical Name |
3,5,8-trihydroxy-2-(4-hydroxyphenyl)-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~37.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2303 mL | 11.1513 mL | 22.3025 mL | |
| 5 mM | 0.4461 mL | 2.2303 mL | 4.4605 mL | |
| 10 mM | 0.2230 mL | 1.1151 mL | 2.2303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
